Ivohart

Ivabradine Hydrochloride, the active ingredient in Ivohart, is an If channel inhibitor presented as a tablet for oral use. It treats chronic stable angina and heart failure with reduced ejection fraction in adults.

GNH USA supplies Ivohart as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivohart acts on the cardiac If current to manage ischemic heart conditions and heart failure.

Chronic stable angina: reduces the frequency of angina attacks and improves exercise tolerance. Heart failure with reduced ejection fraction: lowers heart rate, improves symptoms and may reduce hospitalizations. Ischemic heart disease: helps control heart rate without compromising contractility.

Adverse reactions may occur with ivabradine therapy.

Common Side Effects: - Visual disturbances (phosphenes) - Bradycardia - Headache - Dizziness - Fatigue - Blurred vision

Serious or Rare Side Effects: - Symptomatic bradycardia requiring medical intervention - Atrial fibrillation or other arrhythmias - Severe hypotension - Myocardial infarction - Heart block - Persistent visual impairment

Use ivabradine with caution in specific clinical situations.

Cardiac monitoring: patients with baseline heart rate below 60 bpm should be observed. Concomitant bradycardic agents: avoid excessive heart‑rate reduction when combined with beta‑blockers or digoxin. Severe hepatic impairment: dose adjustment may be required. Pregnancy and lactation: contraindicated unless benefits outweigh risks. Drug interactions: review concomitant CYP3A4 inhibitors before prescribing. Store at ambient temperature: keep in the original pack, protect from moisture and light.

Ivabradine may interact with several medicines that affect heart rate or metabolism.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase ivabradine plasma levels. - Concomitant bradycardic agents (e.g., beta‑blockers, digoxin): risk of excessive bradycardia. - Other If channel inhibitors: additive heart‑rate lowering effect.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin): may require dose adjustment. - Antihypertensives: potential enhanced blood‑pressure reduction. - QT‑prolonging drugs: monitor ECG for arrhythmia risk.